Eptifibatide Injection Shortage

• • Eptifibatide injection, Amneal, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70121-1003-01
  • Eptifibatide injection, Amneal, 2 mg/mL, 10 mL vial, 1 count, NDC 70121-1002-01
  • Eptifibatide injection, Baxter, 0.75 mg/mL, 100 mL vial, 1 count, NDC 00338-9558-10
  • Eptifibatide injection, Eugia US, 0.75 mg/mL, 100 mL vial, 1 count, NDC 55150-0218-99
  • Eptifibatide injection, Eugia US, 2 mg/mL, 10 mL vial, 1 count, NDC 55150-0219-10
  • Eptifibatide injection, Eugia US, 2 mg/mL, 100 mL vial, 1 count, NDC 55150-0220-99
  • Eptifibatide injection, Sagent, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70860-0305-51
  • Eptifibatide injection, Sagent, 2 mg/mL, 10 mL vial, 1 count, NDC 25021-0409-10

• • Accord has temporarily discontinued eptifibatide injection.
  • Akorn ceased operations in February 2023.
  • Amneal did not provide a reason for the shortage.
  • Baxter states the shortage is due to increased demand.
  • Eugia did not provide a reason for the shortage.
  • Merck discontinued Integrilin in October 2020. Wholesalers may continue to sell inventory until product expires.
  • Viatris has eptifibatide injection available.
  • Sagent states the shortage is due to manufacturing delay.
  • Slate Run has eptifibatide injection available.

• • Eptifibatide injection, Mylan Institutional (Viatris), 0.75 mg/mL, 100 mL vial, 1 count, NDC 67457-0631-10
  • Eptifibatide injection, Mylan Institutional (Viatris), 2 mg/mL, 10 mL vial, 1 count, NDC 67457-0629-10
  • Eptifibatide injection, Mylan Institutional (Viatris), 2 mg/mL, 100 mL vial, 1 count, NDC 67457-0630-10
  • Eptifibatide injection, Sagent, 0.75 mg/mL, 100 mL vial, 1 count, NDC 25021-0408-51
  • Eptifibatide injection, Slate Run Pharmaceuticals, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70436-0027-80
  • Eptifibatide injection, Slate Run Pharmaceuticals, 2 mg/mL, 10 mL vial, 1 count, NDC 70436-0026-80

Estimated Resupply Dates

• • Amneal has eptifibatide 0.75 mg/mL 100 mL vials and 2 mg/mL in 10 mL vials on long-term back order and the company cannot estimate a release date.
  • Baxter has eptifibatide 0.75 mg/mL in 100 mL vials on back order and the company estimates a release date in June 2024.
  • Eugia has all eptifibatide injection presentations on intermittent back order and the company is releasing supplies as they become available.
  • Sagent has eptifibatide 2 mg/mL 10 mL vials on back order and the company cannot estimate a release date. The 0.75 mg/mL 100 mL vials (NDC 70860-0305-51) are also on back order and the company cannot estimate a release date.